Search details
1.
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
N Engl J Med
; 390(19): 1770-1780, 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38587249
2.
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation
; 145(21): 1581-1591, 2022 05 24.
Article
in English
| MEDLINE | ID: mdl-35510542
3.
Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry.
Am Heart J
; 258: 149-156, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36669711
4.
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Circulation
; 142(8): 734-747, 2020 08 25.
Article
in English
| MEDLINE | ID: mdl-32795086
5.
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Diabetes Obes Metab
; 23(1): 29-38, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32844557
6.
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Circulation
; 139(17): 2022-2031, 2019 04 23.
Article
in English
| MEDLINE | ID: mdl-30786725
7.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet
; 393(10166): 31-39, 2019 01 05.
Article
in English
| MEDLINE | ID: mdl-30424892
8.
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
Circulation
; 137(7): 684-692, 2018 02 13.
Article
in English
| MEDLINE | ID: mdl-29084737
9.
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
J Thromb Thrombolysis
; 47(3): 353-360, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30511258
10.
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
Circulation
; 134(12): 861-71, 2016 Sep 20.
Article
in English
| MEDLINE | ID: mdl-27576775
11.
Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.
Vasc Med
; 24(2): 159-161, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30868939
12.
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Diabetes Care
; 46(1): 156-164, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-36399721
13.
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
JAMA Cardiol
; 8(5): 503-509, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36857035
14.
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
Lancet Diabetes Endocrinol
; 11(4): 233-241, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36878239
15.
Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome.
Eur J Prev Cardiol
; 29(6): 895-902, 2022 05 06.
Article
in English
| MEDLINE | ID: mdl-33624052
16.
Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry.
J Am Heart Assoc
; 11(9): e024451, 2022 05 03.
Article
in English
| MEDLINE | ID: mdl-35470683
17.
Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.
Clin Cardiol
; 45(8): 831-838, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35855557
18.
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
JAMA Cardiol
; 7(9): 914-923, 2022 09 01.
Article
in English
| MEDLINE | ID: mdl-35857296
19.
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58.
Diabetes Care
; 45(4): 938-946, 2022 04 01.
Article
in English
| MEDLINE | ID: mdl-35015847
20.
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Diabetes Care
; 45(10): 2350-2359, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35997319